Skip to content

Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial

Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00522262
Enrollment
320
Registered
2007-08-29
Start date
2002-06-30
Completion date
2007-07-31
Last updated
2015-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

Breast Neoplasms, Exercise, Physical activity, Estrone, Estradiol, Adiposity, Breast density, Mammographic density, Insulin-Like Growth Factor I, Insulin Resistance, Women, Postmenopause

Brief summary

The purpose of the ALPHA Trial is to examine the physiologic changes that occur in a woman's body when she begins exercising that may be related to a change in her risk of getting breast cancer.

Detailed description

The goal of this study is to examine how a one-year exercise intervention, as compared to a usual sedentary lifestyle, influences specific biologic mechanisms that are hypothesized to be operative in the association between physical activity and breast cancer risk. These biologic mechanisms include sex hormone concentrations (estrone, estradiol and sex-hormone binding globulin); measures of adiposity and obesity; mammographic density; insulin-like growth factors; and insulin resistance. A two-centered, two-armed randomized controlled trial (RCT) of exercise and risk factors for breast cancer will be conducted. Approximately 334 postmenopausal, sedentary women will be recruited to the study. Participants will be randomized to one of two groups: an exercise intervention, or a control group. The intervention group will undertake five weekly exercise sessions of 60 minutes each; three will be facility-based and two will be home-based each week. The Edmonton and Calgary exercise oncology facilities will be working in collaboration, and each will include both the controls and exercise intervention arms of the trial. The exercise intervention will last for 12 months. The control group will be asked not to change their usual level of activity during that time. Baseline assessments will be obtained of serum sex hormones (estrone and estradiol), measures of obesity and adiposity, mammographic density, serum insulin growth factor (IGF)-1, insulin resistance, aerobic capacity, and psychosocial health measures. At the end of the study, all baseline assessments will be repeated and compared between the two groups. This study will specifically address identified gaps in knowledge, in terms of examining the simultaneous effect of physical activity on several biologic mechanisms in a controlled trial setting, building on evidence from the only other randomized controlled trial on this topic. Strengths of the proposal include the multi-centered setting (utilizing facilities in both Calgary and Edmonton), and the collaboration of an experienced multi-disciplinary research team from across North America.

Interventions

Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.

Sponsors

Canadian Breast Cancer Research Alliance
CollaboratorOTHER
University of Alberta
CollaboratorOTHER
University of Calgary
CollaboratorOTHER
AHS Cancer Control Alberta
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 74 Years
Healthy volunteers
Yes

Inclusion criteria

* Female * Age 50-74 at baseline * Postmenopausal * Moderately sedentary lifestyle * Live in Calgary or Edmonton, Alberta, Canada * English-speaking * Willing to be randomized * Body-mass index 22.0-40.0 * Breast tissue density \>=0%

Exclusion criteria

* Previous invasive cancer in last 5 years * Major co-morbidities * Unable to participate in exercise program * Current smoker * Current excessive drinker * Hormone replacement therapy use in previous 2 years * Drugs that may influence one or more study outcomes

Design outcomes

Primary

MeasureTime frameDescription
Changes in estrone, estradiol and adiposity levelsUp to 12 monthsThe effect of the exercise intervention on sex steroid and adiposity levels after one year is examined.

Secondary

MeasureTime frameDescription
Changes in mammographic density, insulin resistance and inflammatory markersUp to 12 monthsThe effect of the exercise intervention after one year is examined.
The effect of the exercise intervention on exercise adherence and quality of life.Up to 12 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026